The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

ABSTRACT:

Objective

The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker-defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease-modifying therapeutic trials.

Methods

A total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.

Results

Approximately 9% of enrolled subj

SUBMITTER: Marek K 

PROVIDER: S-EPMC6292383 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature